Immunoliposome-mediated drug delivery to Plasmodium -infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy

Moles, Ernest; Urbán, Patricia; Jiménez-Dı́az, Marı́a Belén; Viera-Morilla, Sara; Angulo-Barturen, Íñigo; Busquets, Montserrat; Fernàndez‐Busquets, Xavier

doi:10.1016/j.jconrel.2015.05.284

Cited by 78 publications

(119 citation statements)

References 65 publications

(154 reference statements)

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…The slow drug release observed in case of ammonium sulfate gradient loaded PtCQ-liposomes is necessary for long storage and to avoid drug leaking before reaching their target. 5) Afterward the liposomes would be adsorbed on the cell surface followed by a depletion of the liposomal proton gradient due to the body temperature or liposomes-cell interaction episodes. This depletion leads to accumulation of the weak basic drugs inside the RBC due to the electrochemical gradient resulted from the phospholipid asymmetry in RBC membranes, which maintains negatively charged membranes.…”

Section: )mentioning

confidence: 99%

See 1 more Smart Citation

Effective-Loading of Platinum–Chloroquine into PEGylated Neutral and Cationic Liposomes as a Drug Delivery System for Resistant Malaria Parasites

Ibrahim

Tagami

Ozeki

2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The trans platinum-chloroquine diphosphate dichloride (PtCQ) is a new type of antimalarial drug used to fight parasites resistant to traditional drugs. PtCQ is synthesized by mixing platinum and chloroquine diphosphate (CQ). This study examines two efficient methods for forming a nanodrug, PtCQ-loaded liposomes, for use as a potential antimalarial drug-delivery system: the thin drug-lipid film method to incorporate the drug into a liposomal membrane, and a remote-loading method to load the drug into the interior of a cationic liposome. The membranes accordingly comprised PEGylated neutral or cationic liposomes. PtCQ was efficiently loaded into PEGylated neutral and cationic liposomes using the thin drug-lipid film method (encapsulation efficiency, EE: 76.1 6.7% for neutral liposomes, 1 : 14 drug-to-lipid weight ratio; 70.4 9.8% for cationic liposomes, 1 : 14 drug-to-lipid weight ratio). More PtCQ was loaded into PEGylated neutral liposomes using the remote-loading method than by the thin drug-lipid film method and the EE was maximum (96.1 4.5% for neutral liposomes, 1 : 7 (w/w)). PtCQ was encapsulated in PEGylated cationic liposomes comprising various amounts of cationic lipids (0-20 mol%; EE: 96.9-92.3%) using the remote-loading method. PEGylated neutral liposomes and cationic liposomes exhibited minimum leakage of PtCQ after two months' storage at 4°C, and further exhibited little release under in vitro culture conditions at 37°C for 72 h. These results provide a useful framework for the design of future liposome-based in vivo drug delivery systems targeting the malaria parasite.

show abstract

Section: )mentioning

confidence: 99%

“…[4][5][6][7] For example, liposomal formulations can increase drug bioavailability and thus increase therapeutic activity, decreasing side effects due to reduced dosing. Plasmodium-infected RBCs are the main chemotherapeutic target because several life stages of the parasite occur in the blood and give rise to the symptoms and pathologies of malaria.…”

mentioning

confidence: 99%

Effective-Loading of Platinum–Chloroquine into PEGylated Neutral and Cationic Liposomes as a Drug Delivery System for Resistant Malaria Parasites

Ibrahim

Tagami

Ozeki

2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…[187] Meanwhile, though infectious disease-causing agents are more commonly targeted using direct antibody-drug conjugates, tethered monoclonal antibodies against erythrocyte glycophorin A have been used to deliver drug-containing nanocarriers to Plasmodium-infected red blood cells. [188] Degradation-labile cytotoxic or therapeutic agents such as siRNAs may also be delivered in antibody-or antibody fragment-conjugated carriers, as evidenced with pathogens such as dengue virus, [189] avian influenza A (H5N1) virus [190] and HIV. [191] …”

Section: Antibodies In Targetingmentioning

confidence: 99%

Adding Functions to Biomaterial Surfaces through Protein Incorporation

et al. 2016

View full text Add to dashboard Cite

The concept of biomaterials has evolved from one of inert mechanical supports with a long-term, biologically inactive role in the body into complex matrices that exhibit selective cell binding, promote proliferation and matrix production, and may ultimately become replaced by newly generated tissues in vivo. Functionalization of material surfaces with biomolecules is critical to their ability to evade immunorecognition, interact productively with surrounding tissues and extracellular matrix, and avoid bacterial colonization. Antibody molecules and their derived fragments are commonly immobilized on materials to mediate coating with specific cell types in fields such as stent endothelialization and drug delivery. The incorporation of growth factors into biomaterials has found application in promoting and accelerating bone formation in osteogenerative and related applications. Peptides and extracellular matrix proteins can impart biomolecule- and cell-specificities to materials while antimicrobial peptides have found roles in preventing biofilm formation on devices and implants. In this progress report, we detail developments in the use of diverse proteins and peptides to modify the surfaces of hard biomaterials in vivo and in vitro. Chemical approaches to immobilizing active biomolecules are presented, as well as platform technologies for isolation or generation of natural or synthetic molecules suitable for biomaterial functionalization.

show abstract

“…[13] In this scenario, the therapeutic agents confined inside the host cell can act on their respective metabolic targets as soon as Plasmodium starts synthesizing these, thus significantly lowering the IC 50 of drugs. In addition, this universal RBC targeting likely provides a second, prophylactic activity, when the immunoliposomal contents are delivered to noninfected erythrocytes, effectively protecting these cells against Plasmodium infection (Figure 2).…”

Section: Preloading Of Uninfected Red Blood Cells With Antimalarial Dmentioning

confidence: 99%

“…In addition, this universal RBC targeting likely provides a second, prophylactic activity, when the immunoliposomal contents are delivered to noninfected erythrocytes, effectively protecting these cells against Plasmodium infection (Figure 2). [13] 4. Targeting Plasmodium stages in the mosquito vector A largely unexplored avenue in antimalarial drug development is targeting the parasite stages in the insect vector itself, an approach being barely investigated in the laboratory, and not implemented yet as part of a clinically feasible alternative therapy.…”

Section: Preloading Of Uninfected Red Blood Cells With Antimalarial Dmentioning

confidence: 99%

Novel strategies for Plasmodium-targeted drug delivery

Fernàndez‐Busquets

2016

Expert Opinion on Drug Delivery

Self Cite

View full text Add to dashboard Cite

Immunoliposome-mediated drug delivery to Plasmodium -infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy

Cited by 78 publications

References 65 publications

Effective-Loading of Platinum–Chloroquine into PEGylated Neutral and Cationic Liposomes as a Drug Delivery System for Resistant Malaria Parasites

Effective-Loading of Platinum–Chloroquine into PEGylated Neutral and Cationic Liposomes as a Drug Delivery System for Resistant Malaria Parasites

Adding Functions to Biomaterial Surfaces through Protein Incorporation

Novel strategies for Plasmodium-targeted drug delivery

Contact Info

Product

Resources

About